Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

CXC Chemokine Receptor 5 Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Threonine367/Serine368 phosphorylation of the CXC Chemokine Receptor 5
pT367/pS368-CXCR5 (phospho-CXC Chemokine...
Threonine367/Serine368 (T367/S368) is a major phosphorylation site of the CXCR5 receptor. The pT367/pS368-CXCR5 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T367/S368...
$ 375.00 *
Details
NEW
Agonist-induced Threonine370/Threonine371 phosphorylation of the CXC Chemokine Receptor 5
pT370/pT371-CXCR5 (phospho-CXC Chemokine...
Threonine370/Threonine371 (T370/T371) is a major phosphorylation site of the CXCR5 receptor. The pT370/pT371-CXCR5 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T370/T371...
$ 375.00 *
Details
NEW
Validation of the CXCR5 Receptor in transfected HEK293 cells
CXCR5 (non-phospho), CXCR5 Chemokine Receptor...
The non-phospho-CXCR5 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human CXCR5. It can be used to detect total CXCR5 receptors in Western blots independent of phosphorylation.
$ 375.00 *
Details

C-X-C chemokine receptor 5 (CXCR5), encoded by CXCR5, is a class A G protein-coupled receptor whose principal endogenous ligand is CXCL13. It signals predominantly through Gi/o and directs cell migration along CXCL13 gradients. CXCR5 is expressed primarily on mature B cells and follicular helper T cells, as well as on subsets of follicular regulatory T cells. It guides these cells into B-cell follicles in secondary lymphoid organs, where their interactions support germinal center formation and antibody maturation. CXCL13 induces rapid phosphorylation of the receptor’s C-terminal tail at Ser367/Thr368 and Ser370/Ser371, promoting β-arrestin recruitment. In experimental systems, β-arrestins are required for efficient CXCR5 desensitization, whereas GRK-dependent receptor internalization can proceed independently of β-arrestins. The anti-CXCR5 antibody PF-06835375, designed to block CXCL13 signaling and deplete CXCR5-expressing cells, has been evaluated in a phase 1 trial. No CXCR5-targeted drug is currently approved for therapeutic use. This nomenclature refers to the human CXCR5 but is highly conserved among species and identical in mice and humans. For more information on CXCR5 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

C-X-C chemokine receptor 5 (CXCR5), encoded by CXCR5 , is a class A G protein-coupled receptor whose principal endogenous ligand is CXCL13. It signals predominantly through Gi/o and directs... read more »
Close window
CXC Chemokine Receptor 5 Antibodies

C-X-C chemokine receptor 5 (CXCR5), encoded by CXCR5, is a class A G protein-coupled receptor whose principal endogenous ligand is CXCL13. It signals predominantly through Gi/o and directs cell migration along CXCL13 gradients. CXCR5 is expressed primarily on mature B cells and follicular helper T cells, as well as on subsets of follicular regulatory T cells. It guides these cells into B-cell follicles in secondary lymphoid organs, where their interactions support germinal center formation and antibody maturation. CXCL13 induces rapid phosphorylation of the receptor’s C-terminal tail at Ser367/Thr368 and Ser370/Ser371, promoting β-arrestin recruitment. In experimental systems, β-arrestins are required for efficient CXCR5 desensitization, whereas GRK-dependent receptor internalization can proceed independently of β-arrestins. The anti-CXCR5 antibody PF-06835375, designed to block CXCL13 signaling and deplete CXCR5-expressing cells, has been evaluated in a phase 1 trial. No CXCR5-targeted drug is currently approved for therapeutic use. This nomenclature refers to the human CXCR5 but is highly conserved among species and identical in mice and humans. For more information on CXCR5 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

Recently viewed